Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGBL2 | Q5U5Z8 | 2/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRE | P78334 | 1/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.36 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29593515 | 1.00 | AGBL2 (0.41) | AGBL2GABRR1POLBALDH1A1TSHR | |
| SCHEMBL15006455 | 0.82 | HTT (0.46) | POLBALDH1A1SMN1; SMN2HSD17B10TDP1 | |
| SCHEMBL30595305 | 0.82 | HTT (0.46) | POLBALDH1A1SMN1; SMN2HSD17B10TDP1 | |
| SCHEMBL27940385 | 0.78 | GABRA5 (0.38) | AGBL2GABRR1ALDH1A1TSHRGABRA5 | |
| SCHEMBL38655175 | 0.77 | SMN1; SMN2 (0.47) | POLBALDH1A1SMN1; SMN2TDP1KDM4E | |
| SCHEMBL27837903 | 0.77 | GABRA5 (0.37) | AGBL2GABRR1POLBALDH1A1TSHR | |
| SCHEMBL28940883 | 0.77 | GABRA5 (0.37) | AGBL2GABRR1ALDH1A1TSHRGABRA5 | |
| SCHEMBL27940310 | 0.77 | AGBL2 (0.38) | AGBL2GABRR1ALDH1A1TSHRGABRA5 | |
| SCHEMBL11962909 | 0.76 | MAPT (0.44) | POLBALDH1A1SMN1; SMN2HSD17B10TDP1 | |
| SCHEMBL27940305 | 0.76 | HCAR2 (0.36) | AGBL2GABRR1POLBALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| CN-116490499-A | Modulators of MYC family protooncogene proteins | 纳罗医疗公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-4204411-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | Nalo Therapeutics (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-3592741-B1 | NOVEL IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS | PFIZER (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-3592741-B1 | NOVEL IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS | PFIZER (US) | 2023-02-15 | — | — | EP | disclosed |
| CN-111051304-B | Imidazo [4,5-c ] quinoline derivatives as LRRK2 inhibitors | 辉瑞大药厂 | 2022-12-27 | — | — | CN | disclosed |
| US-11312713-B2 | Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors | PFIZER INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11312713-B2 | Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors | PFIZER INC. (US) | 2022-04-26 | — | — | US | disclosed |
| CN-105130967-A | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors | ARRAY BIOPHARMA INC | 2015-12-09 | — | — | CN | disclosed |
| CN-103649076-B | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TRKA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-09-09 | — | — | CN | disclosed |
| CN-103649076-A | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors | ARRAY BIOPHARMA INC | 2014-03-19 | — | — | CN | disclosed |
| CN-101611014-B | Amidopyrazoles as FGFR inhibitors | ASTRAZENECA AB | 2012-05-30 | — | — | CN | disclosed |
| US-8067409-B2 | Protein kinase inhibitors | ABBOTT LABORATORIES (US) | 2011-11-29 | — | — | US | disclosed |
| EP-2222682-A1 | IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Abbott Laboratories (US) | 2010-09-01 | — | — | EP | disclosed |
| CN-101611014-A | Amidopyrazoles as FGFR inhibitors | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | CN | disclosed |
| US-20090253723-A1 | PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
| WO-2009070516-A1 | IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2003106435-A1 | FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF | SANKYO COMPANY, LIMITED (JP) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253723-A1 | PROTEIN KINASE INHIBITORS | PACSIN2, MAP3K20, PHKG1 | AGBL2 813/4885GABRR1 1968/4885POLB 1211/4885 |
| US-11312713-B2 | Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors | LRRK2, PARK7, BRCA1 | AGBL2 2638/4885GABRR1 3288/4885POLB 1476/4885 |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | AGBL2 2028/4885GABRR1 3519/4885POLB 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.